Abstract
BackgroundInfliximab have proven to be effective in spondyloarthritis. Previous studies suggest that patients in clinical remission may benefit from dose reduction or pharmacological tapering without relapse.ObjectivesTo study the evolution of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
